BMY stock

BMY Stock Bounces After Earnings – Recent Performance Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 (closing at $42.99) marketbeat.com. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector (which was roughly flat to slightly up over the same period) nasdaq.com. By comparison, an index of large pharmaceutical stocks was